Rhabdomyolysis due to probable interaction between simvastatin and ritonavir.
Straightforward reports of unusual drug experiences are included in this section. While selected references may be cited, the purpose of a Drug Experience report is not to present an extensive review of the literature. A related section, Grand Rounds; includes papers that are well-documented patient case reports with a thorough review of the important literature to help put the case in perspective. Authors should report serious adverse drug reactions to the FDA medical products reporting program (MedWatch). Such reporting will not jeopardize the chances that AJHP will publish manuscripts on the same drug reactions.
Cheng
Cindy H
CH
Department of Pharmacy Services, Sinai Hospital, Baltimore, MD, USA.
Miller
Christine
C
Lowe
Christopher
C
Pearson
Vincent Earl
VE
D019380:Anti-HIV Agents / Q000009:adverse effects*; D000924:Anticholesteremic Agents / Q000009:adverse effects*; D051544:Cytochrome P-450 CYP3A; D065607:Cytochrome P-450 Enzyme Inhibitors; D004347:Drug Interactions; D005260:Female; D006801:Humans; D008875:Middle Aged; D006899:Mixed Function Oxygenases / Q000037:antagonists & inhibitors; D012206:Rhabdomyolysis / Q000139:chemically induced*; D019438:Ritonavir / Q000009:adverse effects*; D019821:Simvastatin / Q000009:adverse effects*
D019380:Anti-HIV Agents; D000924:Anticholesteremic Agents; D065607:Cytochrome P-450 Enzyme Inhibitors; D019821:Simvastatin; D006899:Mixed Function Oxygenases; C104464:CYP3A protein, human; D051544:Cytochrome P-450 CYP3A; D019438:Ritonavir